<DOC>
	<DOCNO>NCT02766699</DOCNO>
	<brief_summary>The purpose Cerebral EDV study determine safety tolerability EGFR ( V ) -EDV-Dox order establish best dose level use future study . The study also examine body 's immune response EGFR ( V ) -EDV-Dox assess effective treatment patient recurrent glioblastoma multiforme ( GBM ) .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability Immunogenicity EGFR ( V ) -EDV-Dox Subjects With Recurrent Glioblastoma Multiforme ( GBM )</brief_title>
	<detailed_description>This open-label , Phase 1 , dose exploration preliminary immunogenicity study single agent EGFR ( V ) -EDV-Dox subject recurrent glioblastoma ( GBM ) . Eligible subject enrol study receive EGFR ( V ) -EDV-Dox administer weekly 7 week via IV 20 minute infusion , follow radiological evaluation week 8 ( 1 Cycle ) . Subjects may continue receive subsequent cycle EGFR ( V ) -EDV-Dox unless subject becomes intolerant investigational product ( IP ) , withdraw consent individual longer receive clinical benefit ( factor take consideration disease progression radiologically clinically , clinical benefit quality life ) . Tumour assessment repeat 7 week cycle ( week 8 ) . The study take place two part , Part 1 ( Dose Exploration ) Part 2 ( Dose Expansion ) . Part 1 - Dose Exploration ass safety tolerability multiple dos drug two dose level ( 5 x 10^9 8 x 10^9 ) enroll prior Part 2 . Three subject recruit per dose level . Enrollment begin 5 x 10^9 dose level , decision enroll 8 x 10^9 dose level follow comprehensive safety evaluation standard 3 + 3 dose escalation study design . Part 2 - Dose Expansion conduct pending safety result Part 1 provide guidance regard recommend phase 2 dose ( RP2D ) . Subjects treat assessed outlined Part 1 . If 0 3 subject , 1 6 subject , experience dose limit toxicity ( DLTs ) 5 x 10^9 dose level Part 1 , additional subject total 10 recruit dose level Part 2 . Similarly , 0 3 subject , 1 6 subject , experience DLTs 8 x 10^9 dose level Part 1 , additional subject total 10 recruit dose level Part 2 . If dose level tolerate , total 10 subject per dose level enrol . A safety follow-up visit must perform 30 ( +5 ) day last dose drug subjects.All subject discontinue investigational product withdrawn full consent participate study continue long term follow-up phase . Long term follow-up continue approximately every 1 month 12 month , 30 ( +5 ) day follow-up visit , approximately every 2-3 month extent subject survival .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>1 . Karnofsky Performance Status ( KPS ) ≥ 60 % . 2 . Life expectancy ≥ 3 month . 3 . Pathologically document , definitively diagnose recurrent World Health Organization ( WHO ) Grade IV astrocytoma ( GBM ) . 4 . Participant must archive tumor tissue available initial diagnosis subsequent relapse ( ) Grade IV GBM submission central review Investigational sit local laboratory . 5 . Recurrence progression disease ( confirm MRI measurable RANO criterion ) follow receipt standard care therapy , include maximum safe surgical resection , standard adjuvant radiation/temozolomide maintenance temozolomide treatment . 6 . Participant receive ≤ 1 chemotherapy regimen temozolomide ( ie , carboplatin , 1,3bis ( 2chloroethyl ) 1nitrosourea ( BCNU ) , Lomustine ( CCNU ) , etc ) . 7 . Participant may receive steroid therapy time enrollment ( stable dose ≤ 4 mg/day dexamethasone steroid equivalent ) . 8 . Ability undergo MRI evaluation . 9 . Participant ≥ 1 site bidimensionally measurable disease measure use contrast enhance MRI . 10 . Hematological function : White blood cell count ( WBC ) ≥ 3.0 x 109/L Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Hemoglobin &gt; 9 g/dL Prothrombin time ( PT ) partial thromboplastin time ( PTT ) &lt; 1.5 x upper limit normal ( ULN ) International normalize ratio ( INR ) &lt; 1.5 x ULN 11 . Renal function : Blood urea nitrogen ( BUN ) &lt; 30 mg/dL Creatinine serum level ≤ 1.5 x ULN Or creatinine clearance ≥ 60 mL/minute subject serum creatinine outside normal range ( calculate use CockcroftGault equation ) . 12 . Hepatic function : Aspartate aminotransferase ( AST ) &lt; 2.5 x ULN ( 3 x ULN subject chronic anticonvulsive therapy know increase transaminase ) . Alanine aminotransferase ( ALT ) &lt; 2.5 x ULN ( 3 x ULN subject chronic anticonvulsive therapy know increase transaminase ) . Alkaline phosphatase ( ALP ) &lt; 2.5 x ULN ( 3 x ULN subject chronic anticonvulsive therapy ) . Total bilirubin ≤ 1 x ULN ( unless elevate due Gilbert 's syndrome extrahepatic source denote increased indirect bilirubin fraction . Subjects ≥1 x ULN test direct bilirubin fraction indirect fraction calculate ) . 13 . Adequate cardiac function leave ventricular ejection fraction ( LVEF ) ≥ 55 % baseline . 14 . Serum phosphate level within normal limit ( 2.4 4.1 milligram per deciliter mg/dL ) baseline . 15 . Subject meet reproductive criterion follow : Female subject nonreproductive potential ( ie , post menopausal history menses ≥ 1 year folliclestimulating hormone ( FSH ) level consistent postmenopausal status ; OR history hysterectomy ; OR history bilateral tubal ligation ; OR history bilateral oophorectomy ) . Female subject childbearing potential must negative serum pregnancy test within 7 day prior 1st dose , 7 day prior , urine pregnancy test must perform 1st dose . The female subject must willing use highly effective method birth control period therapy 6 month follow last study IP administration . Highly effective method birth control include sexual abstinence , hormonal birth control , intrauterine device ( woman ) , vasectomy condom spermicide ( men ) combination barrier method . Male subject willing use highly effective method birth control period therapy 6 month follow last IP administration . All study subject must willing ensure correspond sexual partner practice method highly effective birth control duration . 1 . History central nervous system bleed define stroke intraocular bleed within 6 month enrollment . 2 . Evidence acute intracranial / intratumoral hemorrhage , except participant stable grade 1 hemorrhage . 3 . History coronary artery disease , without angina pectoris myocardial infarction , symptomatic congestive heart failure ( New York Heart Association &gt; Class II ) , uncontrolled hypertension ( systolic &gt; 160 mmHg diastolic &gt; 100 mmHg ) cardiac arrhythmia require antiarrrhythmic therapy . 4 . Clinically significant electrocardiogram ( ECG ) change enrollment obscure ability ass PR , QT , QRS interval ; congenital long QT syndrome . 5 . Active infection require treatment . 6 . History malignancy , except : adequately treat nonmelanoma skin cancer , curatively treated insitu cancer , solid tumor curatively treat evidence disease ≥ 2 year . 7 . Known positive test human immunodeficiency virus infection ( HIV ) , active hepatitis B hepatitis C infection . 8 . Receipt therapies procedure prior first dose include : Radiation therapy ( within 12 week Study Day 1 recover toxic effect therapy ) . Bevacizumab® antiangiogenic therapy . Gliadel® Wafer ( within 6 month Study Day 1 , recover toxic effect therapy ) . Immunotherapeutic agent , vaccine , monoclonal antibody therapy ( within 4 week Study Day 1 recover toxic effect cancer therapy ) . Temozolomide chemotherapy ( within 4 week Study Day 1 6 week nitrogen mustard , recover toxic effect cancer therapy ) . Anticoagulation therapy ( within 7 day Study Day 1 ) , except low molecular weight heparin low dose aspirin . Other investigational therapy ( within 30 day Study Day 1 ) . Medications know cause QTc interval prolongation ( within 7 day OR five halflives prior Study Day 1 , whichever long ) . Surgical resection brain tumor ( within 4 week Study Day 1 recover acute side effect therapy except neurological effect ) . Any major surgery ( within 4 week Study Day 1 , recover effect surgery ) . 9 . Subject know allergic/hypersensitivity investigational component excipients ( doxorubicin , trehalose , monoclonal antibody therapy , penicillin class antibiotic , gentamicin ( aminoglycosides ) , ciprofloxacin hydrochloride ( quinolones ) ) . 10 . Evidence antiSalmonella Lipopolysaccharide ( LPS ) antibodies screen . 11 . If female , pregnant breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Astrocytoma , Grade IV</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Drug Delivery Systems</keyword>
	<keyword>Molecular Targeted Therapy</keyword>
	<keyword>Nanoparticles</keyword>
	<keyword>Disease Progression</keyword>
	<keyword>Recurrence</keyword>
	<keyword>Brain Neoplasms</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Receptor , Epidermal Growth Factor</keyword>
	<keyword>Antibodies , Bispecific</keyword>
</DOC>